ArticleFrontiers in cardiovascular medicine2022
The monomeric C-reactive protein level is associated with the increase in carotid plaque number in patients with subclinical carotid atherosclerosis.
Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A meta-analysis investigating the relationship between inflammation in autoimmune disease, elevated CRP, and the risk of dementia.Frontiers in immunology · 2023Pooled it
- Circulating biomarkers of carotid plaque vulnerability: current evidence, emerging markers, and barriers to clinical implementation.Biomarker research · 2026Review
- HIV infection is independently associated with carotid plaque burden and echogenic characteristics.Open heart · 2026Article
- The Pathogenic Role of C-Reactive Protein in Diabetes-Linked Unstable Atherosclerosis.International journal of molecular sciences · 2025Review
- mCRP-Associated Vascular Pathophysiology in Progression and Outcome of Intracerebral Hemorrhage.International journal of molecular sciences · 2025Review
- Methylation risk score of C-reactive protein associates sleep health with related health outcomes.Communications biology · 2025Article
- C-reactive protein conformations and their association with the IL-1β/IL-6 pathway in ocular inflammatory conditions.Frontiers in immunology · 2025Article
- Review
- mCRP-Induced Focal Adhesion Kinase-Dependent Monocyte Aggregation and M1 Polarization, Which Was Partially Blocked by the C10M Inhibitor.International journal of molecular sciences · 2024Article
- Higher monomeric C-reactive protein levels are associated with premature coronary artery disease.Frontiers in immunology · 2024Article
- Article
- Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives.International journal of molecular sciences · 2023Review
- C-reactive protein isoforms as prognostic markers of COVID-19 severity.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The high-sensitivity C-reactive protein (hsCRP) assay measures the level of the pentameric form of CRP in blood. Currently, there are no available assays measuring the level of the monomeric form of CRP (mCRP), produced at sites of local inflammation. We developed an assay measuring the mCRP level in blood plasma with functional beads for flow cytometry. The assay was used to measure the mCRP level in 80 middle-aged individuals with initially moderate cardiovascular SCORE risk. By the time of the mCRP measurement, the patients have been followed up for subclinical carotid atherosclerosis progression for 7 years. Ultrasound markers of subclinical atherosclerosis, which included plaque number (PN) and total plaque height (PH), were measured at baseline and at the 7th-year follow-up survey. Inflammatory biomarkers, including mCRP, hsCRP, inteleukin-6 (IL-6) and von Willebrand factor (VWF) level, were measured at the 7th-year follow-up survey. The median level of mCRP was 5.2 (3.3; 7.1) μg/L, hsCRP 1.05 (0.7; 2.1) mg/L, IL-6 0.0 (0.0; 2.8) pg/mL, VWF 106 (77; 151) IU/dL. In the patients with the mCRP level below median vs. the patients with the median mCRP level or higher, change from baseline in PN was 0.0 (0.0; 1.0) vs. 1.0 (1.0; 2.0) and PH 0.22 (-0.24; 1.91) mm vs. 1.97 (1.14; 3.14) mm, respectively (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.